Effects of an exclusive human-milk diet in preterm neonates on early vascular aging risk factors (NEOVASC): study protocol for a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial.
Cardiovascular risk
Human milk
Human-milk-based fortifier
Neonatology
Prematurity
Preterm
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
31 Jul 2021
31 Jul 2021
Historique:
received:
20
03
2021
accepted:
10
07
2021
entrez:
1
8
2021
pubmed:
2
8
2021
medline:
4
8
2021
Statut:
epublish
Résumé
Preterm birth accounts for approximately 11% of all livebirths globally. Due to improvements in perinatal care, more than 95% of these infants now survive into adulthood. Research has indicated a robust association between prematurity and increased cardiovascular risk factors and cardiovascular mortality. While the innate adverse effects of prematurity on these outcomes have been demonstrated, therapeutic strategies on the mitigation of these concerning developments are lacking. The primary objective of the NEOVASC clinical trial is therefore to investigate whether the administration of a prolonged exclusive human-milk diet in preterm infants is capable of alleviating the harmful effects of preterm birth on the early development of cardiovascular risk factors. The NEOVASC study is a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial conducted in four Austrian tertiary neonatal care facilities. The purpose of the present trial is to investigate the effects of a prolonged exclusive human-milk-diet devoid of bovine-milk-based food components on cardiovascular and metabolic risk factors at 1, 2, and 5 years of corrected age. Primary outcomes include assessments of fasting blood glucose levels, blood pressure levels, and the distensibility of the descending aorta using validated echocardiographic protocols at 5 years of corrected age. The test group, which consists of 200 preterm infants, will therefore be compared to a control group of 100 term-born infants and a historical control group recruited previously. Given the emerging implications of an increased cardiovascular risk profile in the potentially growing population of preterm infants, further research on the mitigation of long-term morbidities in formerly preterm infants is urgently warranted. Further optimizing preterm infants' nutrition by removing bovine-milk-based food components may therefore be an interesting approach worth pursuing. ClinicalTrials.gov NCT04413994 . Registered on 4 June 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Preterm birth accounts for approximately 11% of all livebirths globally. Due to improvements in perinatal care, more than 95% of these infants now survive into adulthood. Research has indicated a robust association between prematurity and increased cardiovascular risk factors and cardiovascular mortality. While the innate adverse effects of prematurity on these outcomes have been demonstrated, therapeutic strategies on the mitigation of these concerning developments are lacking. The primary objective of the NEOVASC clinical trial is therefore to investigate whether the administration of a prolonged exclusive human-milk diet in preterm infants is capable of alleviating the harmful effects of preterm birth on the early development of cardiovascular risk factors.
METHODS
METHODS
The NEOVASC study is a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial conducted in four Austrian tertiary neonatal care facilities. The purpose of the present trial is to investigate the effects of a prolonged exclusive human-milk-diet devoid of bovine-milk-based food components on cardiovascular and metabolic risk factors at 1, 2, and 5 years of corrected age. Primary outcomes include assessments of fasting blood glucose levels, blood pressure levels, and the distensibility of the descending aorta using validated echocardiographic protocols at 5 years of corrected age. The test group, which consists of 200 preterm infants, will therefore be compared to a control group of 100 term-born infants and a historical control group recruited previously.
DISCUSSION
CONCLUSIONS
Given the emerging implications of an increased cardiovascular risk profile in the potentially growing population of preterm infants, further research on the mitigation of long-term morbidities in formerly preterm infants is urgently warranted. Further optimizing preterm infants' nutrition by removing bovine-milk-based food components may therefore be an interesting approach worth pursuing.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04413994 . Registered on 4 June 2020.
Identifiants
pubmed: 34332629
doi: 10.1186/s13063-021-05445-9
pii: 10.1186/s13063-021-05445-9
pmc: PMC8325296
doi:
Banques de données
ClinicalTrials.gov
['NCT04413994']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509Informations de copyright
© 2021. The Author(s).
Références
Breastfeed Med. 2016 Mar;11(2):70-4
pubmed: 26789484
Lancet. 2001 Feb 10;357(9254):413-9
pubmed: 11273059
Diabetologia. 2020 Mar;63(3):508-518
pubmed: 31802143
Circulation. 2005 Nov 29;112(22):3430-6
pubmed: 16301344
Acta Paediatr Suppl. 2004 Dec;93(446):26-33
pubmed: 15702667
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2268-2274
pubmed: 27659099
JAMA. 2011 Sep 21;306(11):1233-40
pubmed: 21934056
Pediatrics. 2013 Apr;131(4):e1240-63
pubmed: 23509172
Int J Cardiol. 2014 Mar 15;172(2):e361-3
pubmed: 24461981
Pediatr Res. 2017 May;81(5):787-794
pubmed: 28141791
J Hypertens. 2008 Jun;26(6):1049-57
pubmed: 18475139
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
J Pediatr. 2013 Dec;163(6):1592-1595.e1
pubmed: 23968744
Lancet. 2004 May 15;363(9421):1571-8
pubmed: 15145629
Breastfeed Med. 2014 Jul-Aug;9(6):281-5
pubmed: 24867268
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
J Pediatr. 2010 Apr;156(4):562-7.e1
pubmed: 20036378
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
N Engl J Med. 2019 Jul 18;381(3):243-251
pubmed: 31314968
J Am Heart Assoc. 2019 Jun 18;8(12):e012274
pubmed: 31164036
J Thorac Cardiovasc Surg. 2005 Apr;129(4):730-9
pubmed: 15821637
Lancet. 2013 Aug 3;382(9890):417-425
pubmed: 23746775
J Pediatr. 2018 Oct;201:49-54.e1
pubmed: 29960764
J Pediatr. 2019 Jul;210:69-80.e5
pubmed: 30992219
JAMA Pediatr. 2019 Aug 1;173(8):736-743
pubmed: 31157896
Acta Paediatr. 2017 Sep;106(9):1409-1437
pubmed: 28419544
JAMA. 2019 Oct 22;322(16):1580-1588
pubmed: 31638681
Eur Heart J. 2020 Apr 21;41(16):1542-1550
pubmed: 31872206
Lancet. 2016 Jan 30;387(10017):475-90
pubmed: 26869575
N Engl J Med. 2004 Nov 18;351(21):2179-86
pubmed: 15548778
Lancet. 2008 Jan 12;371(9607):164-75
pubmed: 18191687
Lancet Child Adolesc Health. 2019 Jun;3(6):408-417
pubmed: 30956154
Obes Rev. 2014 Oct;15(10):804-11
pubmed: 25073871
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753
JAMA. 2014 Feb 12;311(6):587-96
pubmed: 24519298
Hypertension. 2012 Feb;59(2):226-34
pubmed: 22158643
Lancet. 1993 Apr 10;341(8850):938-41
pubmed: 8096277
PLoS One. 2016 Dec 13;11(12):e0168162
pubmed: 27959909